Published in
Nature Reviews Immunology, Nature Publishing Group
Content
Nature Reviews Immunology, Published online: 07 August 2025; doi:10.1038/s41577-025-01207-9
Fifty years ago, Köhler and Milstein introduced the world to hybridoma technology for the generation of monoclonal antibodies. Scientists have subsequently built upon this seminal discovery to develop antibody-based therapies for numerous diseases, with millions of patients benefiting from such drugs. To mark 50 years of monoclonal antibodies, this Review from Chan, Martyn and Carter provides an overview of how antibody engineering strategies have continued to improve antibody-based therapeutics, chiefly focusing on antibody-mediated targeting of B cells and also human epidermal growth factor receptor 2 (HER2)+ cancers. The authors also highlight the promise of emerging tools, including artificial intelligence, for development of the next generation of antibody-based therapeutics.Paul J. Carter
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 111
- Comments 0